FORTE BIOSCIENCES INC (FBRX)
Health Care · Clinical-stage monoclonal antibody therapeutics for autoimmune diseases · NASDAQ
A clinical-stage biotech developing an anti-CD122 antibody (FB102) to modulate immune cells in autoimmune diseases, with promising early celiac disease data and trials underway in vitiligo and alopecia areata.
What FORTE BIOSCIENCES INC does
Forte Biosciences is a clinical-stage biopharmaceutical company developing FB102, a proprietary anti-CD122 monoclonal antibody intended to treat autoimmune and autoimmune-related disorders by antagonizing IL-2/IL-15 receptors that regulate NK cells and T cell subsets. The company is advancing FB102 through Phase 1b and Phase 2 trials in celiac disease, non-segmental vitiligo, and alopecia areata, with positive Phase 1b data in celiac disease showing significant reduction in intestinal intraepithelial lymphocyte counts and gluten challenge-induced symptoms.
Themes: ["monoclonal antibodies / immunotherapy","autoimmune diseases","celiac disease treatment","vitiligo treatment","alopecia areata treatment","NK cell regulation"]
Fundamentals
- Price$36.70 as of 2026-07-09 close
- Market cap$749M as of 2026-07-10
- 1-year return+194.1% as of 2026-07-09 close
- Net margin-158775.0% as of 2026-07-10
- ROE-106.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)-99.8% as of 2026-07-10
- Revenue CAGR (3y)-9.8% SEC XBRL
- Beta2.90 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: FB102 is in Phase 1b/early Phase 2 trials; failure to demonstrate efficacy or safety in ongoing patient studies could halt development and eliminate the company's primary asset","Cash burn and funding risk: The company is unprofitable with negative revenue, cash declining from $77M to $58M in Q1 2026, and will require additional financing to continue development through late-stage trials","Competitive and regulatory risk: No approved treatments currently exist for celiac disease, but competition from established immunology players and regulatory approval pathways remain uncertain"]
Competitors & peers
- Gossamer Bio (GOSS) – autoimmune/immunotherapy focus
- Acceleron Pharma / Merck – broad immunotherapy platforms
- Calithera Biosciences – immune-mediated disorder therapeutics
- Arena Pharmaceuticals – autoimmune and immune disorders
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.